Theravance Discloses CYPRESS Phase 3 Miss and FDA Path Forward for Ampreloxetine
TBPH sits 30% above its 52-week low of $13.08.
Summary
Theravance disclosed that the Phase 3 CYPRESS study of ampreloxetine missed its primary endpoint, but post hoc analyses showed significant treatment effects in a focused patient population. The FDA indicated an additional pivotal trial could support approval, and a Type C meeting has been granted to align on study design.
Key Events · Product Development and Regulatory · TBPH
-
CYPRESS Primary Endpoint Missed
The Phase 3 CYPRESS study (Study 0197) of ampreloxetine in nOH associated with MSA failed to meet its primary endpoint — change in OHSA composite score at week 8 during randomized withdrawal was not statistically significant.
-
Post Hoc Analyses Show Signal
In a confirmed symptomatic nOH population (n=47), post hoc longitudinal analyses showed statistically significant treatment effects: average OHSA LS mean difference -1.06 (p=0.001), OHDAS -1.27 (p<0.001), and OHQ -1.24 (p<0.001).
-
FDA Path Forward Requires New Trial
At a May 2026 Type B meeting, the FDA indicated the existing data package would not support approval, but an additional pivotal trial leveraging prior data could offer a path forward. A Type C meeting was requested in July 2026 and granted to align on future study design.
-
CVR Value Tied to Ampreloxetine
Ampreloxetine is the compound subject to the contingent value right (CVR) in the pending Zymeworks acquisition. The missed primary endpoint and need for an additional trial materially increase the risk that the CVR will never pay out.
Analysis · TBPH · Life Sciences
Theravance revealed that the Phase 3 CYPRESS study of ampreloxetine missed its primary endpoint, but post hoc analyses in a confirmed symptomatic nOH population showed statistically significant treatment effects. The FDA indicated the current data package would not support approval, but an additional pivotal trial could offer a path forward, and a Type C meeting has been granted to align on study design. This matters because ampreloxetine is the asset tied to the contingent value right (CVR) in the pending Zymeworks acquisition — the CVR's value depends entirely on this drug's future development and approval. The disclosure clarifies that the CVR's underlying asset faces a longer, riskier regulatory path than the headline $17/share cash deal might suggest.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TBPH was trading at $17.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $884.2M. The 52-week trading range was $13.08 to $21.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.